Abstract:The detrimental physical, mental, and socioeconomic effects of substance use disorders (SUDs) have been apparent to the medical community for decades. However, it has become increasingly urgent in recent years to develop novel pharmacotherapies to treat SUDs. Currently, practitioners typically rely on monotherapy. Monotherapy has been shown to be superior to no treatment at all for most substance classes. However, many randomized controlled trials (RCTs) have revealed that monotherapy leads to poorer outcomes when compared with combination treatment in all specialties of medicine. The results of RCTs suggest that monotherapy frequently fails since multiple dysregulated pathways, enzymes, neurotransmitters, and receptors are involved in the pathophysiology of SUDs. As such, research is urgently needed to determine how various neurobiological mechanisms can be targeted by novel combination treatments to create increasingly specific yet exceedingly comprehensive approaches to SUD treatment. This article aims to review the neurobiology that integrates many pathophysiologic mechanisms and discuss integrative pharmacology developments that may ultimately improve clinical outcomes for patients with SUDs. Many neurobiological mechanisms are known to be involved in SUDs including dopaminergic, nicotinic, N-methyl-D-aspartate (NMDA), and kynurenic acid (KYNA) mechanisms. Emerging evidence indicates that KYNA, a tryptophan metabolite, modulates all these major pathophysiologic mechanisms. Therefore, achieving KYNA homeostasis by harmonizing integrative pathophysiology and pharmacology could prove to be a better therapeutic approach for SUDs. We propose KYNA-NMDA-α7nAChRcentric pathophysiology, the "conductor of the orchestra," as a novel approach to treat many SUDs concurrently. KYNA-NMDA-α7nAChR pathophysiology may be the "command center" of neuropsychiatry. To date, extant RCTs have shown equivocal findings across comparison conditions, possibly because investigators targeted single pathophysiologic mechanisms, hit wrong targets in underlying pathophysiologic mechanisms, and tested inadequate monotherapy treatment. We provide examples of potential combination treatments that simultaneously target multiple pathophysiologic mechanisms in addition to KYNA. Kynurenine pathway metabolism demonstrates the greatest potential as a target for neuropsychiatric diseases. The investigational medications with the most evidence include memantine, galantamine, and N-acetylcysteine. Future RCTs are warranted with novel combination treatments for SUDs. Multicenter RCTs with integrative pharmacology offer a promising, potentially fruitful avenue to develop novel therapeutics for the treatment of SUDs.

Substance Use Disorder Treatment: Opportunities for Interdisciplinary Collaboration in Neurology and Beyond

Opioid use disorder: current trends and potential treatments

Integrative Pharmacology in the Treatment of Substance Use Disorders

Therapeutic options and challenges for substances of abuse

"The post-COVID era": challenges in the treatment of substance use disorder (SUD) after the pandemic

IUPHAR Review: New strategies for medications to treat substance use disorders

The Nexus of Aging and Substance Use: A Scoping Review of Therapeutic Modalities for Geriatric Substance Use Disorders

Opioid Use Disorder: Treatments and Barriers

Stimulant use among patients in opioid treatment settings: Provider perspectives

Strengthening Neuroplasticity in Substance Use Recovery Through Lifestyle Intervention

Future pharmacological treatments for substance use disorders

Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder

A Perspective from the Field: Five Interventions to Combat the Opioid Epidemic and Ending the Dichotomy of Harm-reduction versus Abstinence-Based Programs

Engaging Integrated Health Teams to Decrease the Risk of Controlled Substance Use for Individuals With Serious Mental Illness

Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine

Personalized medicine and opioid use disorder

Substance use disorder bridge clinics: models, evidence, and future directions

Innovation in the treatment, interventions and systems of care for opioid use disorder: opportunities to understand multimorbidities

Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date

890. Bridging the Gap to Help Address the Opioid Crisis: A Novel Model of Care to Integrate Substance Use, Mental Health, and Infectious Disease Services